Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has entered into a research and licensing collaboration with Eli Lilly and Company. The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.

Under the agreement, Insilico will leverage its validated Pharma.AI platform and proven drug discovery capabilities to generate, design and optimise candidate compounds against targets defined by Lilly. The company is eligible to receive over USD 100 million, including upfront and milestone payments, along with tiered royalties on net sales upon commercialisation of any  drug products resulting from the collaboration. 

"Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognises Insilico's AI-driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide,” said Alex Zhavoronkov, Founder and Co-CEO of Insilico Medicine.  

The latest agreement marks a deepening of the partnership between the two companies, which began with an AI-based software licensing deal in 2023.

Headquartered in Boston and Hong Kong, Insilico Medicine operates globally with offices and laboratories in Montreal, Shanghai, Yixing and Abu Dhabi.